Message from the CEO – December 2022
By Karen Loudon / December 14, 2022
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development...
Read More
Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch
By Karen Loudon / December 7, 2022
Ian Nisbet and Alan Trounson, AO Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard...
Read More
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
By Karen Loudon / November 8, 2022
Melbourne, Victoria, Australia - 08 November 2022 The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced...
Read More
Cartherics is ‘Frocking Up’ this month in support of ovarian cancer research
By Karen Loudon / October 17, 2022
Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for...
Read More
Cartherics unveils new $4M lab to develop cancer immunotherapy treatments in Victoria
By Karen Loudon / October 13, 2022
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has...
Read More
Cartherics granted first US patent for multiple development candidates
By Karen Loudon / October 6, 2022
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced...
Read More
Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers
By Karen Loudon / September 30, 2022
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together...
Read More
3 Cheers for a Cartherics Board Member
By Karen Loudon / June 16, 2022
Bryan Williams ranked among the world’s most prominent scientists By Leigh Dayton, 16 June 2022 Cartherics is delighted to announce...
Read More
She’s an Adventurer, Advocate, Author and a Cancer Survivor
By Karen Loudon / June 9, 2022
Now Heather Hawkins is a member of the Cartherics Board By Leigh Dayton 9 June 2022 It’s official. As of...
Read More
Presentation at the Locust Walk Stem Cell Tx Conference
By carth_admin / April 8, 2022
Dr Ian Nisbet Chief Operating Officer Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner...
Read More
Congratulations to Cartherics CEO
By carth_admin / April 1, 2022
Alan Trounson is ranked among the world’s most prominent scientists
Read More
Cartherics CEO discusses the importance of industry-academic collaboration with new partner
By carth_admin / March 30, 2022
In the following interview with ARMI Alan Trounson discusses the importance and challenges of translation
Read More
7th Innate Killer Summit 2022, Dr Nicholas Boyd Presenting
By Karen Loudon / March 25, 2022
7th Innate Killer Summit (San Diego, California) Cartherics Chief Development Officer, Dr Nicholas Boyd The innate cell therapy field is...
Read More
By Karen Loudon / March 4, 2022
The 4th Allogeneic Cell Therapies Summit is the leading industry-dedicated meeting that considers pre-clinical development, translation, manufacturing, supply and storage of allogeneic cell therapies to improve the...
Read More
Presentation at the Next Generation CAR-TCR Summit (London, UK)
By Karen Loudon / February 23, 2022
Presentation at the Next Generation CAR-TCR Summit (London, UK) Cartherics Chief Development Officer, Dr Nicholas Boyd CAR-T immunotherapy has exploded...
Read More
